$29.30
-0.37-1.25%
Last update: 8:30 AM
15 minutes delayed
Comments
Loading...
RXO
RXONYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
RXO (NYSE:RXO) Stock, Analyst Ratings, Price Targets, Forecasts
RXO Inc has a consensus price target of $21.82 based on the ratings of 19 analysts. The high is $30 issued by Barclays on July 16, 2024. The low is $16 issued by Susquehanna on March 26, 2024. The 3 most-recent analyst ratings were released by Barclays, JP Morgan, and Stephens & Co. on July 16, 2024, July 9, 2024, and May 6, 2024, respectively. With an average price target of $25.67 between Barclays, JP Morgan, and Stephens & Co., there's an implied -12.40% downside for RXO Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
JP Morgan
Stephens & Co.
Susquehanna
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for RXO
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 2.39% | Barclays | Brandon Oglenski | $24 → $30 | Maintains | Overweight | Get Alert |
| 07/09/2024 | Buy Now | -14.68% | JP Morgan | Brian Ossenbeck | $16 → $25 | Maintains | Underweight | Get Alert |
| 06/12/2024 | Buy Now | — | Benchmark | Christopher Kuhn | — | Reiterates | → Hold | Get Alert |
| 05/15/2024 | Buy Now | — | Raymond James | Felix Boeschen | — | Reinstates | → Market Perform | Get Alert |
| 05/06/2024 | Buy Now | -24.91% | Stephens & Co. | Daniel Imbro | → $22 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 04/19/2024 | Buy Now | — | Benchmark | Christopher Kuhn | — | Reiterates | → Hold | Get Alert |
| 03/26/2024 | Buy Now | -45.39% | Susquehanna | Bascome Majors | $15 → $16 | Maintains | Negative | Get Alert |
| 03/25/2024 | Buy Now | -45.39% | Susquehanna | Bascome Majors | $15 → $16 | Maintains | Negative | Get Alert |
| 02/13/2024 | Buy Now | -24.91% | Oppenheimer | Scott Schneeberger | $23 → $22 | Maintains | Outperform | Get Alert |
| 02/09/2024 | Buy Now | -48.81% | Susquehanna | Bascome Majors | $18 → $15 | Maintains | Negative | Get Alert |
| 02/08/2024 | Buy Now | -24.91% | B of A Securities | Ken Hoexter | $25 → $22 | Downgrade | Buy → Neutral | Get Alert |
| 01/10/2024 | Buy Now | -24.91% | Stifel | J. Bruce Chan | $20 → $22 | Maintains | Hold | Get Alert |
| 01/10/2024 | Buy Now | -21.5% | Vertical Research | Jeffrey Kauffman | → $23 | Downgrade | Buy → Hold | Get Alert |
| 10/16/2023 | Buy Now | -41.98% | Stifel | J. Bruce Chan | $19 → $17 | Maintains | Hold | Get Alert |
| 10/11/2023 | Buy Now | -45.39% | JP Morgan | Brian Ossenbeck | $17 → $16 | Downgrade | Neutral → Underweight | Get Alert |
| 10/03/2023 | Buy Now | -55.63% | Susquehanna | Bascome Majors | $14 → $13 | Maintains | Negative | Get Alert |
| 10/02/2023 | Buy Now | -38.57% | Morgan Stanley | Ravi Shanker | $20 → $18 | Maintains | Equal-Weight | Get Alert |
| 08/31/2023 | Buy Now | -52.22% | Susquehanna | Bascome Majors | $19 → $14 | Downgrade | Neutral → Negative | Get Alert |
| 08/07/2023 | Buy Now | -18.09% | Oppenheimer | Scott Schneeberger | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 08/03/2023 | Buy Now | -31.74% | Morgan Stanley | Ravi Shanker | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | -35.15% | Stephens & Co. | Jack Atkins | $23 → $19 | Maintains | Equal-Weight | Get Alert |
| 07/12/2023 | Buy Now | -35.15% | Wolfe Research | Scott Group | → $19 | Downgrade | Peer Perform → Underperform | Get Alert |
| 07/06/2023 | Buy Now | -31.74% | Morgan Stanley | Ravi Shanker | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/09/2023 | Buy Now | -31.74% | Susquehanna | Bascome Majors | → $20 | Initiates | → Neutral | Get Alert |
| 05/24/2023 | Buy Now | -7.85% | Barclays | Brandon Oglenski | → $27 | Initiates | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | -28.33% | Wells Fargo | Allison Poliniak | $22 → $21 | Maintains | Equal-Weight | Get Alert |
| 04/04/2023 | Buy Now | — | Benchmark | Christopher Kuhn | — | Initiates | → Hold | Get Alert |
| 02/27/2023 | Buy Now | -24.91% | Cowen & Co. | Jason Seidl | → $22 | Initiates | → Market Perform | Get Alert |
| 02/09/2023 | Buy Now | -21.5% | UBS | Joseph Parkhill | $20 → $23 | Maintains | Neutral | Get Alert |
| 02/09/2023 | Buy Now | -24.91% | Goldman Sachs | Jordan Alliger | $20 → $22 | Maintains | Neutral | Get Alert |
| 02/09/2023 | Buy Now | -18.09% | Oppenheimer | Scott Schneeberger | $21 → $24 | Maintains | Outperform | Get Alert |
| 02/08/2023 | Buy Now | -31.74% | Stephens & Co. | Jack Atkins | → $20 | Maintains | Equal-Weight | Get Alert |
| 01/11/2023 | Buy Now | -41.98% | Stifel | J. Bruce Chan | $20 → $17 | Downgrade | Buy → Hold | Get Alert |
| 01/09/2023 | Buy Now | -35.15% | JP Morgan | Brian Ossenbeck | → $19 | Initiates | → Neutral | Get Alert |
| 12/20/2022 | Buy Now | -38.57% | Wells Fargo | Allison Poliniak | → $18 | Initiates | → Equal-Weight | Get Alert |
| 12/09/2022 | Buy Now | -31.74% | UBS | Thomas Wadewitz | → $20 | Initiates | → Neutral | Get Alert |
| 12/09/2022 | Buy Now | -31.74% | Morgan Stanley | Ravi Shanker | → $20 | Initiates | → Equal-Weight | Get Alert |
| 12/06/2022 | Buy Now | -14.68% | Jefferies | Stephanie Moore | → $25 | Initiates | → Buy | Get Alert |
| 12/05/2022 | Buy Now | — | Raymond James | Felix Boeschen | — | Initiates | → Market Perform | Get Alert |
| 11/30/2022 | Buy Now | -24.91% | B of A Securities | Ken Hoexter | → $22 | Initiates | → Buy | Get Alert |
| 11/22/2022 | Buy Now | -28.33% | Oppenheimer | Scott Schneeberger | → $21 | Initiates | → Outperform | Get Alert |
| 11/22/2022 | Buy Now | -31.74% | Goldman Sachs | Jordan Alliger | → $20 | Initiates | → Neutral | Get Alert |
| 11/21/2022 | Buy Now | -7.85% | Vertical Research | Jeffrey Kauffman | → $27 | Initiates | → Buy | Get Alert |
| 11/10/2022 | Buy Now | — | Wolfe Research | Scott Group | — | Initiates | → Peer Perform | Get Alert |
| 11/04/2022 | Buy Now | -31.74% | Stifel | J. Bruce Chan | → $20 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for RXO (RXO) stock?
The latest price target for RXO (NYSE:RXO) was reported by Barclays on July 16, 2024. The analyst firm set a price target for $30.00 expecting RXO to rise to within 12 months (a possible 2.39% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RXO (RXO)?
The latest analyst rating for RXO (NYSE:RXO) was provided by Barclays, and RXO maintained their overweight rating.
When was the last upgrade for RXO (RXO)?
There is no last upgrade for RXO
When was the last downgrade for RXO (RXO)?
The last downgrade for RXO Inc happened on February 8, 2024 when B of A Securities changed their price target from $25 to $22 for RXO Inc.
When is the next analyst rating going to be posted or updated for RXO (RXO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RXO, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RXO was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating RXO (RXO) correct?
While ratings are subjective and will change, the latest RXO (RXO) rating was a maintained with a price target of $24.00 to $30.00. The current price RXO (RXO) is trading at is $29.30, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.